Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q3 2020 · 10-Q
Revenue$44.03M$44.03M+32.7% vs Q3 2019 Net Income$33.00M$33.00MN/M vs Q3 2019 EPS Diluted$0.35$0.35N/M vs Q3 2019 Operating Income$32,330,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,768,000N/M Margins · derivedOperating margin73.4%+232.7 pt vs Q3 2019
Net margin75.0%+224.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end